Mutations in THSD7B have the potential to suppress cell death-related signaling activity while promoting the upregulation of invasion and metastasis-related pathways and downregulating immune response pathways, thereby impacting SCLC patient prognosis.[14] The THSD7B rs13405020 SNP is also known to be related to prognostic outcomes in individuals with NSCLC.[15] Protein interaction analyses have demonstrated that THSD7B is capable of interacting with both SPON family proteins as well as THBS1. This evidence concerns the gene THSD7B and small cell lung carcinoma.